Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z. +16 more·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1607751

Cited by (1,433)

Items 601–700 of 1,433

DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma
Scott Ryan Goldsmith, Mark Aaron Fiala, Brandon Wang, Mark A. Schroeder, Tanya Marya Wildes, Armin Ghobadi, Keith E Stockerl-Goldstein, Ravi Vij · 2020 · Annals of Hematology
Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy
Takaki Kikuchi, Shigeru Kusumoto, Yasuhito Tanaka et al. · 2020 · Journal of the Japan Society of the Reticuloendothelial System
KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients
Salvatore Palmieri, Stefano Rocco, Orsola Vitagliano et al. · 2020 · Annals of Hematology
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
Benedetta Dalla Palma, Valentina Marchica, Maria Teresa Catarozzo, Nicola Giuliani, Fabrizio Accardi · 2020 · Journal of Clinical Medicine
Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients
Francesca Bonello, Mario Boccadoro, Alessandra Larocca · 2020 · Cancers
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
Xavier P Leleu, Meral Beksaç, Takaaki Chou, Meletios Athanasios Dimopoulos, Sung‐Soo Yoon, Henry Miles Prince, Luděk Pour, Tatiana V. Shelekhova, Ajai Chari, Monica Khurana et al. · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
Key regulators of sensitivity to immunomodulatory drugs in cancer treatment
Shichao Wang, Zhiyue Li, Shaobing Gao · 2021 · Biomarker Research
Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older
Pashna N. Munshi, David H. Vesole, Andrew St. Martin · 2021 · Cancer
Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
Despina Fotiou, Meletios Athanasios Dimopoulos, Efstathios Kastritis · 2022 · Cancers
Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft
U Gössi, Barbara Jeker, Behrouz Mansouri Taleghani, Ulrike Bacher, Urban Novak, Daniel C. Betticher, Thomas Egger, Thilo Zander, Thomas Pabst · 2018 · Hematological Oncology
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018
Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos · 2019 · Clinical Lymphoma Myeloma & Leukemia
Flexibly coupled multiprocessors for image processing
Myung Hoon Sunwoo, J.K. Aggarwal · 1990 · Journal of Parallel and Distributed Computing
Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial
Sikander Ailawadhi, Joseph R Mikhael, Betsy R LaPlant, Kristina M. Laumann, Shaji Kunnathu Kumar, Vivek Roy, David Dingli, Peter Leif Bergsagel, Francis K. Buadi, S. Vincent Rajkumar et al. · 2017 · Leukemia
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population
Jiří Minařík, Luděk Pour, Vladimír Maisnar, Ivan Špıčka, Alexandra Jungová, Tomáš Jelı́nek, Lucie Brožová, Petra Krhovská, Vlastimil Ščudla, Roman Hájek · 2018 · Biomedical Papers
AL Amyloidosis: Unfolding a Complex Disease
Rebecca Lu, Tiffany A. Richards, PhD, ANP-BC · 2019 · Journal of the Advanced Practitioner in Oncology
Clinical efficacy of retreatment of daratumumab‐based therapy ( D2 ) in daratumumab‐refractory multiple myeloma
Al-Ola A. Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed, Wei Cui, Leyla Osman Shune, Joseph P. McGuirk, Meera Mohan, Ghulam Rehman Mohyuddin, Aimaz Afrough, Omar Abed Alkharabsheh et al. · 2023 · European Journal Of Haematology
Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma
Mimi Najjar, John McCarron, Edward R. Scheffer Cliff, Katherine Berger, David P. Steensma, Samer Al Hadidi, Rajshekhar Chakraborty, Aaron Michael Goodman, Eric Anto, Tom Greene et al. · 2023 · JAMA Network Open
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study
Verónica González‐Calle, Paula Rodríguez‐Otero, Anna Maria Sureda, Felipe de Arriba, Marta Reinoso Segura, Paz Ribas, Ana Pilar González, Yolanda González, Albert Oriol, Joaquín Martínez‐López et al. · 2024 · Haematologica
Management of Multiple Myeloma
Shaji Kunnathu Kumar · 2018 · Journal of the National Comprehensive Cancer Network
Seeking Convergence and Cure with New Myeloma Therapies
Priya Choudhry, Derek C. Galligan, Arun P. Wiita · 2018 · Trends in cancer
A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies
Roberto De Luca, Paul Kachel, Klara Kropivšek, Berend Snijder, Markus Gabriel Manz, Dario Neri · 2018 · Protein Engineering Design and Selection
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open‐label, phase 1/2 study
Torben Plesner, Hendrik‐Tobias Arkenau, Francesca Gay, Monique C. Minnema, Mario Boccadoro, Philippe Moreau, Jamie D. Cavenagh, Aurore Perrot, Jacob P. Laubach, Jakub Krejcik et al. · 2019 · British Journal of Haematology
Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis
Jiasheng Wang, Yeseong D. Kim · 2020 · International Journal of Hematology
Safety of ninety-minute daratumumab infusion
Jeffrey Lombardi, Mathieu Boulin, Madeline Devaux, Amélie Cransac, Pauline Pistre, Corinne Pernot, Alexandre Payssot, Ingrid Lafon, Denis Caillot, Pauline Gueneau · 2020 · Journal of Oncology Pharmacy Practice
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
Alessandro Gozzetti, Francesca Bacchiarri, Vincenzo Sammartano et al. · 2020 · Frontiers in Oncology
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
Larysa Jessica Sanchez, Joshua Ryan Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Sunil Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai Chari · 2021 · Therapeutic Advances in Hematology
Metabolic Vulnerabilities in Multiple Myeloma
Julia S.L. Lim, Phyllis S.Y. Chong, Wee Joo Chng · 2022 · Cancers
What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma
Bruno Almeida Costa, Tarek H. Mouhieddine, Joshua Ryan Richter · 2022 · Targeted Oncology
Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?
Josée Golay · 2017 · Journal of Autoimmunity
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Shih‐Feng Cho, Liang Lin, Lijie Xing, Tengteng Yu, Kenneth Wen, Kenneth Carl Anderson, Yu‐Tzu Tai · 2017 · Antibodies
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison
Suzy Van Sanden, Tetsuro Ito, Joris Diels, Martin Vogel, Andrew R. Belch, Albert Oriol · 2017 · The Oncologist
Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity
Natalie F. Berger, Seunghee Kim‐Schulze, Samir Sunil Parekh · 2018 · Advances in experimental medicine and biology
Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma
Ryo Nakagawa, Yasushi Onishi, Akihisa Kawajiri et al. · 2019 · Annals of Hematology
Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials
Meletios Athanasios Dimopoulos, Philippe Moreau, Shinsuke Iida et al. · 2019 · International Journal of Hematology
Monitoring minimal residual disease in the bone marrow using next generation sequencing
Even Holth Rustad, Eileen Mary Boyle · 2020 · Best Practice & Research Clinical Haematology
Proteomics-inspired precision medicine for treating and understanding multiple myeloma
Matthew Ho, Giada Bianchi, Kenneth Carl Anderson · 2020 · Expert Review of Precision Medicine and Drug Development
Ikaros Proteins in Tumor: Current Perspectives and New Developments
Ruolan Xia, Yuan Cheng, Xuejiao Han, Yuquan Wei, Xiawei Wei · 2021 · Frontiers in Molecular Biosciences
Recent advances in the diagnosis and management of amyloid cardiomyopathy
Petra Nijst, W.H. Wilson Tang · 2021 · Faculty Reviews
NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors
Luana Tomaipitinca, Eleonora Russo, Giovanni Bernardini · 2021 · Molecular Aspects of Medicine
Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland
Petri Mankinen, Ville Vihervaara, Saku Torvinen, Janne A. Martikainen, Erkki J. Soini · 2019 · Journal of Medical Economics
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Huamao Mark Lin, Keith L. Davis, James A. Kaye, Katarina Luptakova, Saurabh P. Nagar, Mohamad Mohty · 2019 · Advances in Hematology
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
Roman Hájek, Michel Delforge, Marc Steffen Raab, Paul Schoen, Lucy DeCosta, Ivan Špıčka, Jakub Radocha, Luděk Pour, Sebastian Gonzalez‐McQuire, Walter Bouwmeester · 2019 · British Journal of Haematology
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Marina Silvia Parisi, Salvatore Leotta, Alessandra Romano, Vittorio Del Fabro, Enrica Antonia Martino, Valeria Calafiore, Rachele Giubbolini, Uroš Markovic, Valerio Leotta, Mary Ann Di Giorgio et al. · 2019 · Journal of Clinical Medicine
Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them
Saurabh Chhabra, Anikó Szabó, Chad Glisch, Gemlyn George, Ravi Kishore Narra, Alexandra M. Harrington, James H. Jerkins, Anita D’Souza, Binod Dhakal, Marcelo C. Pasquini et al. · 2020 · Transplantation and Cellular Therapy
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Dorothea Hose, Martin Schreder, Jochen Hefner, Max Bittrich, Sophia Danhof, Susanne Strifler, Maria‐Theresa Krauth, Renate Schoder, Bettina Gisslinger, Hermann Einsele et al. · 2020 · Journal of Cancer Research and Clinical Oncology
Antibody incidence and red blood cell transfusions in patients on daratumumab
Craig D. Tauscher, Sheila K. Moldenhauer, Sandra C. Bryant, Margaret A. DiGuardo, Eapen K. Jacob · 2021 · Transfusion
Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
Ka-Hei Sun, Yin-Ting Wong, Ka Man Cheung, Carmen Michelle Yuen, Yun-Tat Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum Fan, Yuen-Kiu Chow, Man Fai Law et al. · 2022 · Diagnostics
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
Francesca Bonello, Serena Rocchi, Gregorio Barilà et al. · 2022 · Frontiers in Oncology
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
Alexander M. Lesokhin, Richard LeBlanc, Meletios Athanasios Dimopoulos, Marcelo Capra, Carmelo Carlo‐Stella, Lionel Karlin, Jean‐François Castilloux, Peter A. Forsberg, Gurdeep Parmar, Axel Tosikyan et al. · 2023 · Cancer Medicine
Which therapies will move to the front line for multiple myeloma?
María José Cejalvo, Javier de la Rubia · 2017 · Expert Review of Hematology
Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party
Mohamad Sobh, Mauricette Michallet, Valérie Dubois, Simona Iacobelli, Linda Köster, Anja van Biezen, Nathalie Fegueux, Reza Tabrizi, Jürgen Finke, Jean El Cheikh et al. · 2017 · Haematologica
Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients
Tomáš Jelı́nek, Vladimír Maisnar, Luděk Pour, Ivan Špıčka, Jiří Minařík, Evžen Gregora, Petr Kessler, Michal Sýkora, Hana Fraňková, Dagmar Adamová et al. · 2017 · Current Medical Research and Opinion
Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development
Zhaoyang Teng, Neeraj Gupta, Zhaowei Hua, Guohui Liu, Vivek Samnotra, Karthik Venkatakrishnan, Richard Labotka · 2017 · Clinical and Translational Science
Potent antitumor effect of combination therapy with sub‑optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma
Shiori Kinoshita, Masaki Ri, Takashi Kanamori, Sho Aoki, Takashi Yoshida, Tomoko Narita, Haruhito Totani, Asahi Ito, Shigeru Kusumoto, Takashi Ishida et al. · 2018 · Oncology Letters
ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo
Darren Lath, Clive Buckle, Holly Evans, Matthew Fisher, Jenny M. Down, Michelle Anne Lawson, Andrew Chantry · 2018 · PLoS ONE
A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma
S. Hollmann, Daniel Moldaver, Nik Goyert, Daniel T. Grima, Eric M. Maiese · 2019 · Journal of Managed Care & Specialty Pharmacy
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
Noa Biran, David Samuel DiCapua Siegel, Jesús G. Berdeja, Noopur S Raje, Robert Frank Cornell, Melissa Alsina, Tibor J. Kovacsovics, Belle Fang, Amy Sarah Kimball, Ola Landgren · 2019 · American Journal of Hematology
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma
Dilan Anil Patel, Ragisha Gopalakrishnan, Brian G. Engelhardt, Evonne McArthur, Salyka M. Sengsayadeth, Katie Culos, Michael Thomas Byrne, Stacey Ann Goodman, Bipin N. Savani, Wichai Chinratanalab et al. · 2020 · Bone Marrow Transplantation
Monoclonal antibodies in multiple myeloma
Federico Vozella, Francesca Fazio, Gianfranco Lapietra, Maria Teresa Petrucci, Giovanni Martinelli, Claudio Cerchione · 2021 · Panminerva Medica
Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment
Benjamin Motais, Sandra Charvátová, Zuzana Walek, Matouš Hrdinka, Ryszard Smolarczyk, Tomasz Cichoń, Justyna Czapla, Sebastian Giebel, Michal Šimíček, Tomáš Jelı́nek et al. · 2021 · Cells
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
Lakshmi Chakradhar Yarlagadda, Sravani Gundarlapalli, Richa Parikh, Reid D. Landes, Mathew J. Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel A. Mitma, Clyde Bailey, Kerri Hill et al. · 2021 · Cancers
Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma
Yulu Yang, Rui Chen, Yi Gong · 2022 · Biomaterials
Monoclonal Antibodies in the Treatment of Multiple Myeloma
Niels W.C.J. van de Donk, Sonja Zweegman · 2023 · Hematology/Oncology Clinics of North America
Modern advances in heart transplantation
Pratyaksh K. Srivastava, Michelle Maya Kittleson · 2024 · Progress in Cardiovascular Diseases
CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
Hongjie Wang, Theo Koob, Jonathan R. Fromm · 2024 · Cancer Biology & Therapy
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
Emiliano Barbieri, Enrica Antonia Martino, Elena Rivolti, Micol Quaresima, Ernesto Vigna, Antonino Neri, Fortunato Morabito, Massimo Gentile · 2024 · Expert Opinion on Biological Therapy
Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
Deevyashali S. Parekh, Yun Kyoung Tiger, Kevin Tony Jamouss, Justin Hassani, Maroun Bou Zerdan, Shahzad Raza · 2024 · Cancers
Maintenance and continuous therapy for multiple myeloma
Paul Gerard Guy Richardson, Jacob P. Laubach, Sara Gandolfi, Thierry T.F. Facon, Katja Christina Weisel, Peter O’Gorman · 2018 · Expert Review of Anticancer Therapy
Evaluation of the safety and efficacy of daratumumab outside of clinical trials
Hiroki Kobayashi, Takafumi Tsushima, Toshiki Terao, Yoshiaki Abe, Daisuke Miura, Kentaro Narita, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue · 2019 · International Journal of Hematology
Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease
Anastasios I. Kyriazoglou, Ioannis Ntanasis‐Stathopoulos, Evangelos Terpos, Despina Fotiou, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Maria Gavriatopoulou · 2019 · Clinical Lymphoma Myeloma & Leukemia
Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma
Shannon F. Cope, Kabirraaj Toor, Evan Popoff, Rafaël Fonseca, Ola Landgren, María‐Victoria Mateos, Katja Christina Weisel, Jeroen Paul Jansen · 2020 · Value in Health
Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma
Felix Krummradt, Sandra Sauer, Petra Pavel et al. · 2020 · Transplantation and Cellular Therapy
Primary refractory multiple myeloma: a real-world experience with 85 cases
Artur J. Jurczyszyn, Anna Waszczuk‐Gajda, Jorge Julio Castillo, Katarzyna Krawczyk, Martin Štork, Luděk Pour, Lidia Usnarska‐Zubkiewicz, Stanislaw Potoczek, Iwona Hus, Julio Dávila et al. · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience
Elisabetta Antonioli, Michela Staderini, Sofia Pilerci, Federico Perfetto, Francesco Cappelli, Marco Allinovi, Chiara Nozzoli, Irene Attucci, Alessandra Buzzichelli, Maria Messeri et al. · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
CD38 targeted treatment for multiple myeloma
Tomáš Jelı́nek, Jana Mihályová, Roman Hájek · 2018 · Vnitřní lékařství
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial
Christopher Paul Venner, Richard LeBlanc, Irwindeep Sandhu, Darrell J. White, Andrew R. Belch, Donna Ellen Reece, Christine I. Chen, Sean Dolan, Marc Lalancette, Martha Louzada et al. · 2021 · American Journal of Hematology
Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Thomas G Martin, Nina D. Shah, Joshua Ryan Richter, David H. Vesole, Sandy Wai Kuan Wong, Chiung‐Yu Huang, Deepu Madduri, Sundar Jagannath, David Samuel DiCapua Siegel, Noa Biran et al. · 2021 · Cancer
Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma
Laeth L. George, Mustafa Nadeem Malik, Eric J Miller, Kayla Hicks, Razwana Khanam, Alireza Saterehaseman, Megan C. McNichol, Faiz Anwer · 2021 · Clinical Lymphoma Myeloma & Leukemia
Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
Georg Jeryczynski, Arnold Bolomsky, Hermine Agis, Maria‐Theresa Krauth · 2021 · Cancers
Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Yuji Shimura, Shin‐ichi Fuchida, Aya Nakaya, Tomoki Itou, Ryosuke Yamamura, Hirokazu Tanaka, Hirohiko Shibayama et al. · 2022 · Therapeutic Advances in Hematology
A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies
Haley M. Newman, David T. Teachey · 2022 · International Journal of Molecular Sciences
Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment
Sabine Karam, Mohammad Haidous, Iman Abou Dalle, Amélie Dendooven, Nour M. Moukalled, Amaryllis H. Van Craenenbroeck, Ali A. Bazarbachi, Ben Sprangers · 2023 · Critical Reviews in Oncology/Hematology
Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era
Pavel Klener, Tomáš Etrych, Pavel Klener · 2017 · Current Medicinal Chemistry
Practical Considerations for Antibodies in Myeloma
Jacob P. Laubach, Niels W.C.J. van de Donk, Faith E. Davies, Joseph R Mikhael · 2018 · American Society of Clinical Oncology Educational Book
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
Roberto Mina, Maria Teresa Petrucci, Paolo Corradini, Stefano Spada, Francesca F. Patriarca, Chiara Cerrato, Lorenzo De Paoli, Norbert Pescosta, Roberto Ria, Alessandra Malfitano et al. · 2018 · Clinical Lymphoma Myeloma & Leukemia
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
Yanhua Zheng, Hong-Yuan Shen, Li Xu, Juan Feng, Hailong Tang, Na Zhang, Xiequn Chen, Guangxun Gao · 2018 · Journal of Immunology Research
Therapeutic antibodies for multiple myeloma
Tadao Ishida · 2018 · Japanese Journal of Clinical Oncology
MAIA under the microscope — bringing trial design into focus
Prashant Kapoor, S. Vincent Rajkumar · 2019 · Nature Reviews Clinical Oncology
Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data
Katja Christina Weisel, Heinz Ludwig, Achim Rieth, Andrea Lebioda, Hartmut Goldschmidt · 2019 · Quality of Life Research
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial
Ji Hyun Lee, Yong Park, Ka‐Won Kang, Je‐Jung Lee, Ho Sup Lee, Hyeon‐Seok Eom, Young Rok Do, Jin Seok Kim, Sung‐Soo Yoon, Dong‐Yeop Shin et al. · 2021 · Annals of Hematology
When and How to Treat Relapsed Multiple Myeloma
Nitya Nathwani, Luca Bertamini, Rahul Kumar Banerjee, Francesca Gay, Nina D. Shah, Amrita Y. Krishnan · 2021 · American Society of Clinical Oncology Educational Book
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents
Pamela Becherini, Debora Soncini, Silvia Ravera, Elisa Gelli, Claudia Martinuzzi, Giulia Giorgetti, Antonia Cagnetta, Fabio Guolo, Federico Ivaldi, Maurizio Miglino et al. · 2023 · Antioxidants
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
Hiroshi Handa, Tadao Ishida, Shuji Ozaki, Asuka Mori, Kenichi Kato, Shinsuke Iida · 2023 · PLoS ONE
Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union
Sara Manellari, Umberto M. Musazzi, Paolo Rocco, Paola Minghetti · 2023 · International Journal of Pharmaceutics
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Andrew G Spencer, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark‐David Levin, Pieter Sonneveld, Robert Zygmunt Orlowski, Sung‐Soo Yoon, Saad Z. Usmani et al. · 2023 · Blood Advances
Determining treatment intensity in elderly patients with multiple myeloma
Marco Salvini, Mattia D’Agostino, Francesca Bonello, Mario Boccadoro, Sara Bringhen · 2018 · Expert Review of Anticancer Therapy
Daratumumab and its Use in the Treatment of Relapsed and/or Refractory Multiple Myeloma
Sarah Chehab, Elyse Hall Panjic, Charise L. Gleason, Sagar Lonial, Ajay K. Nooka · 2018 · Future Oncology
A Unique Role of T Helper 17 Cells in Different Treatment Stages of Multiple Myeloma
TingTing Ma, Yichan Zhang, Xuan Zhou, Pinhao Xie, Juan Li · 2019 · Clinical Lymphoma Myeloma & Leukemia
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review
Larysa Jessica Sanchez, Kevin M. Barley, Joshua Ryan Richter, Joseph K. Franz, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Sunil Parekh, Shambavi Richard, Ajai Chari · 2020 · Expert Review of Hematology
Belantamab Mafodotin in the Treatment of Relapsed or Refractory Multiple Myeloma
Semira Sheikh, Eyal Lebel, Suzanne Trudel · 2020 · Future Oncology